401 Impact of Gender: Female Matched Related Donor Versus Male Matched Unrelated Donor on Peripheral Blood Allogeneic Stem Cell Transplant for Male Recipients

Track: Poster Abstracts
Saturday, February 14, 2015, 6:45 PM-7:45 PM
Grand Hall CD (Manchester Grand Hyatt)
Shatha Farhan, M.D. , Hematology/Oncology and Bone Marrow Transplantation, Henry Ford Hospital, Detroit, MI
Edward Peres, M.D. , Hematology/Oncology and Bone Marrow Transplantation, Henry Ford Hospital, Detroit, MI
Danielle Pelland , Henry Ford Hospital, Detroit, MI
Susan Wautelet , Henry Ford Hospital, Detroit, MI
Klodiana Neme, PharmD , Pharmacy, Henry Ford Hospital, Detroit, MI
Nancy Mikulandric, PharmD , Pharmacy, Henry Ford Hospital, Detroit, MI
Kenneth Ruemenapp , Henry Ford Hospital, Detroit, MI
Mary Ann Trapp , Henry Ford Hospital, Detroit, MI
Sarah Szymanski , Henry Ford hospital, Detroit, MI
Nalini Janakiraman, M.D. , Hematology/Oncology and Bone Marrow Transplantation, Henry Ford Hospital, Detroit, MI
Presentation recording not available for download or distribution as requested by the presenting author.

The female donor/male recipient combination increases the risks of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic stem cell transplantation (allo-SCT). To explore the impact of Female matched related donor (F-MRD) versus male matched unrelated donor (M-MUD) on outcome of peripheral blood allo-SCT in male recipients, we undertook a single center retrospective analysis of male adult patients transplanted at our center in the last 10 years. We excluded patients who received donor lymphocyte infusion post SCT.

Methods: Disease-free survival (DFS) and OS were calculated using the Kaplan-Meier estimate. Cumulative incidences (CI) were used for relapse (REL) and GVHD in a competing risks setting, NRM being a competing event for REL, and death for GVHD.

RESULTS: Fifty-six patients were identified and included in this analysis. The median age at transplant was 57 years (19-73). Diseases were AML (n=21), ALL (n=7), NHL (n=9), Hodgkin's disease (n=1), myeloma (n=5), MDS (n=11), CLL (n=1), and CML (n=1). Conditioning regimens were myeloablative (MAC) (n=35), reduced toxicity ablative (n=17) or non myelablative (n=4). Donors were F- MRD (n=24) or M-MUD (n=32). Source of stem cells was peripheral blood in all patients. GVHD prophylaxis consisted of tacrolimus and methotrexate in MRD and tacrolimus, methotrexate and anti-thymocyte globulin in MUD. Of the female donors, 63% had previous pregnancies before donation, 8% had no pregnancies and 29% were unknown. Mean age of female donors was 48 while the mean age for male donors was 35.

The median follow-up was 8 months (0.8-54 months). The median OS for patients who received M-MUD was 8.1 months while it was 14.2 months for patients who received F-MRD (p= 0.72) Fig1. Median DFS for patients who received M-MUD was 6 months while it was 7.2 months for patients who received F-MRD (p= 0.94). The CI rates of aGVHD III-IV, extensive chronic GVHD, REL and NRM at 12 months in M-MUD vs F-MRD were 13% vs 16% (p=0.69), 21% vs 27% (p=0.61), 38% vs 44% (P=0.65), and 16% vs 14% (p=0.79), respectively. The CI of steroid refractory (SR) GVHD in M-MUD vs F-MRD was 24% vs 32% (The Hazard Ratio of SR GVHD in M-MUD vs F-MRD is 0.711 (95% confidence interval is 0.29-1.72, p=0.45)) Fig2. Other variables considered in univariate analysis for SR GVHD were recipient age (p=0.55), disease status (p= 0.64), MAC vs other regimens (p=0.58).

Conclusion: In this small cohort from a single center, we found that compared to M-MUD, F-MRD had a trend for higher rates of SR GVHD after peripheral blood allo-SCT in adult male patients, although not statistically significant. There was no impact of F-MRD compared to M-MUD on OS, DFS, REL, NRM or rates of acute or chronic GVHD. However, the absence of statistical impact should be interpreted with caution given the retrospective design of the study and because we cannot exclude a possible limiting effect of a small number of patients.

Fig 1

Fig 2

C:\Users\SFarhan1\Desktop\CIF Plot SR GVHD (2).png

Disclosures:
Nothing To Disclose